SIREN : 913741963
HOLDING MEDLAND is a French company founded 3 years ago, specialized in the sector Activités des sociétés holding. Based in TOULOUSE (31500), this company of category PME shows in 2023 a net income positive of 57 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-09
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2023 |
|---|---|
| Revenue | N/C |
| Net income | 56 931 € |
| EBITDA | -1 574 € |
| Net margin | N/C |
In 2023, HOLDING MEDLAND generates positive net income of 57 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax.
-1 574 €
-2 411 €
56 931 €
The debt ratio (= Financial debt / Equity x 100) stands at 0%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 0%. Low autonomy: the company heavily depends on external financing (banks, suppliers).
0.0%
0.0%
0.0
In 2023, the debt ratio of HOLDING MEDLAND (0.00) ranks in the bottom 25% of the sector, which is positive. This ratio measures the weight of debt relative to equity. A low ratio indicates a solid financial structure with little dependence on creditors.
In 2023, the financial autonomy of HOLDING MEDLAND (0.0%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.
In 2023, the repayment capacity of HOLDING MEDLAND (0.00) ranks in the bottom 25% of the sector, which is positive. This ratio indicates the number of years needed to repay debt with cash flow. A short capacity reflects controlled debt and good cash generation.
The liquidity ratio (= Current assets / Current liabilities) stands at 32151.74. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
32151.744
0.0
In 2023, the liquidity ratio of HOLDING MEDLAND (32151.74) ranks in the top 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio above 1 ensures comfortable coverage of short-term maturities.
In 2023, the interest coverage of HOLDING MEDLAND (0.0x) ranks above the median of the sector. This ratio indicates how many times operating income covers interest expenses. This comfortable position offers an appreciable safety margin.
Based on 63 transactions of similar company sales
in 2023,
the value of HOLDING MEDLAND is estimated at
531 042 €
(range 96 805€ - 788 020€).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Medium reliability: estimate to be confirmed with in-depth analysis.
Only this financial indicator is available for this company.
This estimate is based on the analysis of 63 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare HOLDING MEDLAND with other companies in the same sector:
Voir toutes les statistiques du secteur Activités des sociétés holding
The revenue of HOLDING MEDLAND is not publicly disclosed (confidential accounts filed with INPI).
Yes, HOLDING MEDLAND generated a net profit of 57 k€ in 2023.
The headquarters of HOLDING MEDLAND is located in TOULOUSE (31500), in the department Haute-Garonne.
The tax return of HOLDING MEDLAND is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
HOLDING MEDLAND operates in the sector Activités des sociétés holding (NAF code 64.20Z). See the 'Sector positioning' section above to compare the company with its competitors.